Skip to main content

Table 1 Baseline characteristics of JIA patients according to ever achieving clinical remission of the disease

From: Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach

  Active Disease
(n = 62)
Clinical Remission
(n = 144)
TOTAL
(n = 206)
p
Female sex, n (%) 44 (71) 103 (72) 147 (71) 0.531
Caucasian ethnicitya, n (%) 55 (89) 136 (94) 191 (93) 0.016
JIA subtype n (%)
 Oligoarticular 24 (39) 83 (58) 107 (52) 0.285
  Persistenta 14 (58) 70 (84) 84 (41) 0.016
  Extended 10 (42) 13 (16) 23 (12)  
 Poliarticular RF - 9 (15) 11 (8) 20 (10)  
 Poliarticular RF + 2 (3) 5 (4) 7 (3)  
 Psoriatic 6 (10) 11 (8) 17 (8)  
 Systemic 4 (7) 13 (9) 17 (8)  
 Enthesitis-related arthritis 13 (21) 17 (12) 30 (15)  
 Undifferentiated 3 (5) 5 (4) 8 (4)  
No uveitis, n (%) 47 (76) 116 (81) 163 (79) 0.277
No comorbiditiesa, n (%) 40 (65) 125 (87) 165 (80) 0.001
Positive ANA, n (%) 36 (58) 103 (72) 139 (68) 0.067
Positive RF, n (%) 3 (5) 6 (4) 9 (4) 0.536
HLA B27 presence, n (%) 13 (21) 18 (13) 31 (15) 0.073
No AE with DMARDa, n (%) 30 (48) 108 (75) 138 (67) 0.001
No biologic DMARDa, n (%) 22 (36) 84 (58) 106 (52) 0.002
  1. n Number, JIA Juvenile idiopathic arthritis, RF- Negative rheumatoid factor, RF+ Positive rheumatoid factor, ANA Antinuclear antibodies, HLA B27 Human leukocyte antigen, AE Adverse event, DMARD Disease modifying antirheumatic drug
  2. ap < 0,05 Statistically significant differences using the χ2